|
|
|
 |
J Randolph Hecht, MD
Clinical Professor of Medicine
Director, UCLA GI Oncology Program
Division of Hematology/Oncology
Department of Medicine
UCLA School of Medicine
Los Angeles, California
|
|
|
|
Click here to download the entire interview |
|
Track 1 |
Introduction by Neil Love, MD |
|
Track 2 |
Mechanism of action of small-molecule tyrosine kinase inhibitor PTK787/ZK |
|
Track 3 |
Dynamic contrast-enhanced MRI as a surrogate marker for response to PTK787/ZK |
|
Track 4 |
Mechanisms of VEGF inhibition |
|
Track 5 |
Differences in the potential roles of VEGF receptors 1, 2 and 3 |
|
Track 6 |
Efficacy of single-agent PTK787/ZK |
|
Track 7 |
Background and design of the CONFIRM-1 and CONFIRM-2 trials |
|
Track 8 |
Early primary endpoint analysis of progression-free survival in CONFIRM-1 |
|
Track 9 |
Importance of pharmacokinetics in the development of VEGF inhibitors |
|
Track 10 |
Correlation between progression-free survival and LDH levels in the CONFIRM trials |
|
Track 11 |
Tolerability of PTK787/ZK |
|
Track 12 |
Potential mechanisms of action of bevacizumab |
|
Track 13 |
Potential rationale for rare bowel perforations associated with bevacizumab |
|
Track 14 |
Incidence of arterial thrombotic events with bevacizumab |
|
Track 15 |
Continuation of bevacizumab after disease progression |
|
Track 16 |
Clinical use of bevacizumab in the adjuvant setting |
|
Track 17 |
Duration of treatment with bevacizumab |
|
Track 18 |
Clinical use of CAPOX in the adjuvant setting |
|
Track 19 |
TREE-1 and TREE-2 trials evaluating oxaliplatin/fluoropyrimidine regimens as first-line
therapy for advanced colorectal cancer |
|
Track 20 |
Ongoing trials evaluating different combinations of biologic agents for
advanced colorectal cancer |
|